Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients

Nakhjavani, Mohammad Reza Jafari; Jafarpour, Mahdi; Ghorbanihaghjo, Amir; Azar, Sima Abedi; Mahdavi, Aida Malek

doi:10.1080/14397595.2018.1551107

Cited by 11 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knani et al indicated that patients with severe RA had lower serum sRAGE concentrations than patients with moderate RA and control subjects [68]. On the contrary, in the study by Jafari-Nakhjavani et al, higher serum sRAGE levels were revealed in RA patients as compared with healthy controls, which correlated positively with the disease stage [73]. In another study, Pullerits et al indicated that blood and synovial levels of sRAGE were not associated with disease duration or acute-phase reactant C-reactive protein (CRP) [67].…”

Section: Non-enzymatic Glycosylation and Advanced Glycation End Productsmentioning

confidence: 93%

Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases

Markina

Gerasimova

Markin

et al. 2020

IJMS

View full text Add to dashboard Cite

Immunoglobulins are the potent effector proteins of the humoral immune response. In the course of evolution, immunoglobulins have formed extremely diverse types of molecular structures with antigen-recognizing, antigen-binding, and effector functions embedded in a single molecule. Polysaccharide moiety of immunoglobulins plays the essential role in immunoglobulin functioning. There is growing evidence that the carbohydrate composition of immunoglobulin-linked glycans, and especially their terminal sialic acid residues, provide a key effect on the effector functions of immunoglobulins. Possibly, sialylation of Fc glycan is a common mechanism of IgG anti-inflammatory action in vivo. Thus, the post-translational modification (glycosylation) of immunoglobulins opens up significant possibilities in the diagnosis of both immunological and inflammatory disorders and in their therapies. This review is focused on the analysis of glycosylation of immunoglobulins, which can be a promising addition to improve existing strategies for the diagnosis and treatment of various immuno-inflammatory diseases.

show abstract

Section: Non-enzymatic Glycosylation and Advanced Glycation End Productsmentioning

confidence: 93%

Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases

Markina

Gerasimova

Markin

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In turn, Han et al demonstrated a strong correlation between plasma level of HMGB1 and TRAb as well as CAS. Literature data report a correlation between RAGE levels in the serum and disease activity of other autoimmune diseases [30]. Studies analyzing the involvement of RAGE and HMGB1 in the pathogenesis of various inflammatory diseases are accompanied by experimental studies showing anti-RAGE/HMGB1 antibodies that prevent chronic inflammation [31,32].…”

Section: Mediators Of Inflammationmentioning

confidence: 99%

RAGE and HMGB1 Expression in Orbital Tissue Microenvironment in Graves’ Ophthalmopathy

Łacheta

Poślednik

Czerwaty

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

Graves’ ophthalmopathy (GO) is a chronic autoimmune inflammatory disorder involving orbital tissues. A receptor for advanced glycation end products (RAGE) and its ligand high mobility group box 1 (HMGB1) protein trigger inflammation and cell proliferation and are involved in the pathogenesis of various chronic inflammatory diseases. This study was aimed to evaluate RAGE and HMGB1 expression in GO to determine its potential clinical significance. To the best of our knowledge, this is the first study showing RAGE and HMGB1 expression in orbital tissue using immunohistochemistry. Sections of orbital adipose tissue obtained from patients diagnosed with GO (23 patients; 36 orbits) and normal controls (NC) (15 patients; 15 orbits) were analyzed by immunohistochemistry for RAGE and HMGB1 expression. Expression profiles were then correlated with clinical data of the study group. RAGE and HMGB1 expression were elevated in GO patients in comparison with NC ( p = 0.001 and p = 0.02 , respectively). We observed a correlation between RAGE expression and occurrence of dysthyroid optic neuropathy (DON) ( p = 0.05 ) and levels of TSH Receptor Antibodies (TRAb) ( p = 0.01 ). Overexpression of RAGE and HMGB1 might be associated with GO pathogenesis. In addition, RAGE and HMGB1 proteins may be considered as promising therapeutic targets, but this requires further research.

show abstract

“…Our study found that with each 1 ng/mL increase in the sRAGE, there was increase in the prediction of RA affliction by 1%. Jafari Nakhjavani et al (36) found higher serum sRAGE levels in patients with RA than in healthy controls, which was positively correlated with disease activity. Others observed an association of low sRAGE levels and RAGE 82Ser polymorphism, which is found more frequently in patients with RA.…”

Section: Discussionmentioning

confidence: 97%

Is There a Feasible Link between Vitamin D Receptor Genotypic and Allelic Frequencies with Analytical Biomarkers of Rheumatoid Arthritis Disease?

Idriss

Selim

El-Hakeim

et al. 2020

J Nutr Sci Vitaminol

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is one of the most widespread autoimmune disorders and it has a genetic background with a variety of genes affecting the degradation of the immune system. Along these lines, we assessed the relationship between the BsmI, and FokI VDR polymorphisms and inflammable records identified with infections activity. Such as interleukins (IL-6, IL-8), hypoxia inducible factor-alpha (HIF-a), soluble receptor of advanced glycation end product (sRAGE), oxidized low-density lipoprotein cholesterol (oxLDL), neutrophil gelatinase-associated lipocalin (NGAL) and procollagen N-propeptide of type III collagen (P3NP) and the allelic frequencies of BsmI VDR rs1544410 and FokI VDR rs2228570 polymorphism on the RA. Total of 131 subjects [70 RA patients and 61 age and sex matched apparently healthy controls (HC)] were monitored for inflammatory biomarkers using ELISA. All patients were screened for the BsmI and FokI using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The all biomarkers were significantly higher in RA patients in comparison with HC. There were positive correlations between NGAL, oxLDL and s-RAGE, oxLDL. On BsmI, 'GG' and ' AG' genotypes were significantly associated with high RA activity as well as the frequency of genotypes ' AG & GG" were higher in high activity RA as compared to low RA activity. However on FokI, was observed that in high activity patients the frequency of 'CC' & 'CT' was more prevalent as compared to low activity ones. These outcomes support the immunoregulatory role of vitamin D which is associated with several inflammatory diseases, signifying a credible anti-inflammatory role in perturbation of the RA.

show abstract

Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients

Cited by 11 publications

References 41 publications

Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases

Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases

RAGE and HMGB1 Expression in Orbital Tissue Microenvironment in Graves’ Ophthalmopathy

Is There a Feasible Link between Vitamin D Receptor Genotypic and Allelic Frequencies with Analytical Biomarkers of Rheumatoid Arthritis Disease?

Contact Info

Product

Resources

About